Brexanolone produces ‘meaningful reductions’ in postpartum depression   

Brexanolone produces ‘meaningful reductions’ in postpartum depression

Most women who received an injection of brexanolone — a positive allosteric modulator of -aminobutyric-acid type A receptors — for postpartum depression had significant and clinically meaningful reductions of the condition at 60 hours vs. placebo, according to findings recently published in The Lancet.

READ FULL ARTICLE ON HELIO.COM

We use cookies to improve your experience. Please read our Privacy Policy or click Accept.
X